Abstracts tagged "pain"

Abstract Number: 1716 • ACR Convergence 2020
Predictors of Unacceptable Pain and Unacceptable Pain with Low Inflammation in Early Rheumatoid Arthritis
Anna Eberhard¹, Tor Olofsson², Stefan Bergman³, Thomas Mandl⁴ and Carl Turesson⁵, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden. Department of Rheumatology, Skåne University Hospital, Lund, Sweden., Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, ⁵Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden
Background/Purpose: Pain is a common and debilitating symptom in patients with rheumatoid arthritis (RA). In early RA it is usually due to ongoing inflammation and…
Abstract Number: 0185 • ACR Convergence 2020
Prevalence of Migraine and Neuropathic Pain in Rheumatic Disease
Sylvain Mathieu¹, Marion Couderc¹, Bruno Pereira¹, Jean-Jacques Dubost¹, Sandrine Malochet-Guinamand², Anne Tournadre², Martin Soubrier¹ and Xavier Moisset², ¹CHU Gabriel Montpied, Clermont-Ferrand, France, ²CHU Gabriel Montpied, Clermont-Ferrand
Background/Purpose: The aim of our study was to assess the prevalence of migraine and neuropathic pain in a sample of patients with chronic inflammatory rheumatism…
Abstract Number: 0736 • ACR Convergence 2020
Identification of Salient Resilience Domains Among Adolescents with Chronic Musculoskeletal Pain and Their Parents
Lauren Pianucci¹, Maitry Sonagra², Daneka Stryker³ and Sabrina Gmuca⁴, ¹Arcadia University, Philadelphia, ²Children's Hospital of Philadelphia, Cherry Hill, NJ, ³Drexel University College of Medicine, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Adolescents with chronic musculoskeletal pain (CMP) and their parents have been found to have low to moderate levels of resilience and resilience levels are…
Abstract Number: 1112 • ACR Convergence 2020
Relationship of Depth-Specific Subchondral Bone Mineral Density and Pain in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Jean Liew¹, JD Johnston², Na Wang³, John Lynch⁴, Cora Lewis⁵, James Torner⁶ and Tuhina Neogi³, ¹University of Washington, Seattle, WA, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Boston University School of Medicine, Boston, MA, ⁴UCSF, San Francisco, CA, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶University of Iowa, Iowa City, IA
Background/Purpose: OA has traditionally been considered a disease of cartilage but early OA changes in subchondral bone may precede cartilage abnormalities. Altered subchondral bone mineral…
Abstract Number: 1553 • ACR Convergence 2020
Optical Tomography Can Accurately Diagnose Lupus Arthritis
Wei Tang¹, Alessandro Marone², Youngwan Kim², Tommy Chen¹, Cathy Guo¹, Leila Khalili¹, Andreas Hielscher² and Anca Askanase³, ¹Columbia University Medical Center, New York, NY, ²Columbia University, New York, NY, ³Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Incapacitating inflammatory arthritis occurs in up to 88% of patients with systemic lupus erythematosus (SLE). Arthritis is present in 70-80% of lupus patients in…
Abstract Number: 1726 • ACR Convergence 2020
Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice
Elston He¹, Pratyusha Yalamanchi², William Arnold³ and Erin Arnold⁴, ¹Synovium, Inc., Philadelphia, PA, ²Michigan Medicine, Ann Arbor, MI, ³Retired, Wilmette, IL, ⁴Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL
Background/Purpose: Patient reported outcomes are integral to measuring patient response to treatment for rheumatoid arthritis (RA). RAPID3 is a patient reported outcome metric that consists…
Abstract Number: 0187 • ACR Convergence 2020
Regional and Widespread Patterns of Non-articular Pain Are Common at RA Diagnosis and Contribute to Poor Outcomes at 12 Months: A Prospective Study of Pain Patterns in Canadians with RA
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward C Keystone⁸, Diane Tin⁹, Carter Thorne⁹, Janet Pope¹⁰, Susan Bartlett³ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹Hospital for Special Surgery, New York, NY, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec, Canada, ⁵Universite de Sherbrooke, Sherbrooke, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Persistent pain can occur in early RA patients, despite improvement in synovitis and may be due to coexisting non-articular pain (NAP). Though NAP is…
Abstract Number: 0737 • ACR Convergence 2020
“It’ll Go Away. There’s Nothing Wrong with you:” the Experience of Pain-Related Stigma Among Adolescents with Pain Amplification Syndrome
Emily Wakefield¹, William Zempsky¹, Rebecca Puhl² and Mark Litt³, ¹Connecticut Children's/University of Connecticut School of Medicine, Hartford, CT, ²Rudd Center for Food Policy & Obesity/University of Connecticut, Hartford, CT, ³University of Connecticut School of Medicine, Farmington, CT
Background/Purpose: Chronic pain in adolescence is a complex and significant medical condition, with a reported prevalence of 11-38%.1 Pain amplification syndrome (PAS), which includes fibromyalgia,…
Abstract Number: 1201 • ACR Convergence 2020
Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials
Peter Taylor¹, Arthur Kavanaugh², Peter Nash³, Janet Pope⁴, Beatrix Bartok⁵, Ken Hasegawa⁵, Shangbang Rao⁵, Sander Strengholt⁶ and Rene Westhovens⁷, ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos BV, Leiden, Netherlands, ⁷University Hospitals Leuven, Belgium, Leuven, Belgium
Background/Purpose: RA patients (pts) often suffer substantial pain despite ongoing treatment (tx) and regard pain control as a top tx goal. Filgotinib (FIL)—a potent, oral…
Abstract Number: 1635 • ACR Convergence 2020
Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database
Amy Kenneally¹, Frédérique Bariguian², Richard Petruschke¹, Arlene Tave³, Jess Edison⁴, Nicholas M. Sicignano⁵ and Francis Barbone¹, ¹GSK Consumer Healthcare, Warren, NJ, ²GSK Consumer Healthcare S.A., Nyon, Switzerland, ³PharmaLex US Corporation, Fairfax, VA, ⁴Walter Reed National Military Medical Center, Bethesda, ⁵Health ResearchTx LLC., Prevose, PA
Background/Purpose: Diclofenac sodium gel 1% (DSG), a topical non-steroidal anti-inflammatory drug (NSAID), is effective for the relief of osteoarthritis (OA) pain in the elbows, wrists,…
Abstract Number: 1739 • ACR Convergence 2020
Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption
Sofia Pazmino¹, Annelies Boonen², Diederik De Cock¹, Veerle Stouten¹, Delphine Bertrand¹, Johan Joly³, Rene Westhovens⁴ and Patrick Verschueren⁵, ¹KU Leuven, Leuven, Belgium, ²Maastricht University Medical Center, Maastricht, Netherlands, ³University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, ⁴University Hospitals Leuven, Belgium, Leuven, Belgium, ⁵University Hospital Leuven, Leuven, Belgium
Background/Purpose: Pain remains the highest priority for improvement to patients with Rheumatoid Arthritis (RA). Analgesic prescription in RA was historically a stand-alone approach and afterwards…
Abstract Number: 0306 • ACR Convergence 2020
Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Taylor Blachley², Kelechi Emeanuru², Sven Richter³, Benoit Guerette³ and Philip Mease⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Amgen Inc., Thousand Oaks, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: The efficacy of apremilast vs placebo for the treatment of oligoarticular PsA of ≤2 years duration is being investigated in the FOREMOST trial (NCT03747939).…
Abstract Number: 0742 • ACR Convergence 2020
Effect of IA OnabotulinumtoxinA and Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia of Mice with Monoarthritis
Hollis Krug¹, Nicole Blanshan², Christopher Dorman² and Sandra Frizelle², ¹Minneapolis VAHCS and University of Minnesota Medical School, Minneapolis, MN, ²Minneapolis VAHCS, Minneapolis
Background/Purpose: Neurotoxins are increasingly being proposed as analgesics for arthritis pain. Phase II and III clinical trials have shown efficacy but with potential toxicities such…
Abstract Number: 1215 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
David Walker¹, Tsutomu Takeuchi², Beatrix Bartok³, Shangbang Rao³, I-Heng Lee⁴, Robin Besuyen⁵, Jacques-Eric Gottenberg⁶ and Mark Genovese³, ¹Northumbria Healthcare Trust, North Shields, United Kingdom, ²Keio Univ School of Medicine, Tokyo, Japan, ³Gilead Sciences, Inc., Foster City, CA, ⁴Gilead Sciences, Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Strasbourg University Hospital, Strasbourg, France
Background/Purpose: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain…
Abstract Number: 1640 • ACR Convergence 2020
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies
Thomas Schnitzer¹, Francis Berenbaum², Philip G Conaghan³, Robert Dworkin⁴, Takaharu Yamabe⁵, Isabelle Davignon⁵, Stefan Wilhelm⁶, Erika Dragon⁷ and Lars Viktrup⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁴University of Rochester School of Medicine and Dentistry, Rochester, NY, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Ltd, Budapest, Hungary
Background/Purpose: Tanezumab is under investigation for the treatment of moderate to severe OA pain. As part of the phase 3 OA program, two randomized, placebo-controlled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].